The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.
 
Yasutoshi Kuboki
Honoraria - Taiho Pharmaceutical
 
Tomohiro Nishina
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda
 
Kensei Yamaguchi
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Merck Serono; Takeda
 
Eiji Shinozaki
Honoraria - Bristol-Myers Squibb; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Yoshito Komatsu
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Research Funding - Bayer; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
 
Satoshi Yuki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Taiho Pharmaceutical
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb Japan (Inst)
 
Hiroki Hara
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Ono Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Miki Fukutani
No Relationships to Disclose
 
Yasue Uchida
No Relationships to Disclose
 
Natsuko Tsukahara
No Relationships to Disclose
 
Hiromi Hasegawa
No Relationships to Disclose
 
Seiko Matsuda
No Relationships to Disclose
 
Wataru Okamoto
No Relationships to Disclose
 
Masahito Yonemura
No Relationships to Disclose
 
Shogo Nomura
Employment - Asahi Kasei (I)
 
Akihiro Sato
Honoraria - AstraZeneca; Dainippon Sumitomo Pharma
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Atsushi Ohtsu
Employment - Celgene (I)
Research Funding - Bristol-Myers Squibb
 
Takayuki Yoshino
Research Funding - Dainippon Sumitomo Pharma